At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 65 enrolled
Drug / intervention
cetylpyridinium chloride +1 moredrug
Likely dose
cetylpyridinium chloride 1.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double Blinded, Placebo-controlled Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia: An Exploratory Pilot Study
In Brief
A Early Phase 1 clinical trial evaluating cetylpyridinium chloride and Placebo for Sarcopenia. Completed, enrolled 65 participants.
Detailed Summary
This study is to assess the impact on the prevention of sarcopenia after taking cetylpyridinium chloride targeting the patients of presarcopenia over the age of 60.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcopenia
Countries--
Collaborators--
Timeline
Early Ph 1CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartNov 2014
First PostedNov 2014
Primary CompletionNov 2015
TodayJul 2026
First PostedNov 21, 2014
Enrollment StartNov 13, 2014
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 11.6 years ago
Interventions
cetylpyridinium chloridedrug
Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.
Placebodrug
Control group takes the placebo for the same period.